Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: VLV032
MIFTS: 66

Vulva Cancer

Categories: Cancer diseases, Endocrine diseases, Rare diseases, Reproductive diseases, Skin diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Vulva Cancer

About this section

MalaCards integrated aliases for Vulva Cancer:

Name: Vulva Cancer 11 14
Vulvar Carcinoma 11 58 16 33
Malignant Neoplasm of Vulva 11 71 31
Carcinoma of Vulva 11 58 71
Vulva Carcinoma 11 53 14
Vulvar Cancer 19 41 75
Vulvar Neoplasms 43 71
Vulval Cancer 11 33
Malignant Tumour of Vulva 33
Malignant Tumor of Vulva 11
Malignant Vulvar Tumor 11
Neoplasm of Vulva 11
Vulval Neoplasm 11
Vulvar Neoplasm 11
Cancer of Vulva 33
Vulvar Tumor 11
Ca Vulva 11

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Reproductive diseases Skin diseases Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 31
ICD11: 33
Orphanet: 58  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 11 DOID:1245 DOID:1294
ICD9CM 34 184.4
MeSH 43 D014846
SNOMED-CT 68 126922007 94143002
ICD10 31 C51 C51.9
Orphanet 58 ORPHA494418
UMLS 71 C0042995 C0375071 C0677055
Sources

Summaries for Vulva Cancer

About this section

MedlinePlus: 41 Vulvar cancer is a rare type of cancer. It forms in a woman's external genitals, called the vulva. The cancer usually grows slowly over several years. First, precancerous cells grow on vulvar skin. This is called vulvar intraepithelial neoplasia (VIN), or dysplasia. Not all VIN cases turn into cancer, but it is best to treat it early. Often, vulvar cancer doesn't cause symptoms at first. However, see your doctor for testing if you notice: A lump in the vulva Vulvar itching or tenderness Bleeding that is not your period Changes in the vulvar skin, such as color changes or growths that look like a wart or ulcer You are at greater risk if you've had a human papillomavirus (HPV) infection or have a history of genital warts. Your health care provider diagnoses vulvar cancer with a physical exam and a biopsy. Treatment varies, depending on your overall health and how advanced the cancer is. It might include surgery, radiation therapy, chemotherapy, or biologic therapy. Biologic therapy boosts your body's own ability to fight cancer. NIH: National Cancer Institute

MalaCards based summary: Vulva Cancer, also known as vulvar carcinoma, is related to vulvar sebaceous carcinoma and vulvar eccrine porocarcinoma, and has symptoms including pelvic pain and pruritus vulvae. An important gene associated with Vulva Cancer is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are TNFR1 Pathway and NFAT and Cardiac Hypertrophy. The drugs Octreotide and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include vulva, lymph node and skin, and related phenotypes are Decreased viability and Increased cell death in HCT116 cells

GARD: 19 Vulvar cancer is the abnormal growth of cells of the vulva, which is part of the female reproductive system and includes the vaginal lips, clitoris, and part of the vagina. Symptoms of Vulvar cancer may consist of a lump (mass), itching, or unusual bleeding. Though the exact cause of this cancer is unknown, older women and those who have human papillomavirus have a higher chance of developing Vulvar cancer.

Orphanet: 58 A group of rare tumors of the vulva comprising HPV-associated and HPV-independent squamous cell carcinomas as the most frequent malignant vulvar tumors, basal cell carcinomas, adenocarcinomas, and Bartholin gland carcinomas. Depending on the type of tumor and disease stage, patients may present with a painless vulvar mass or ulcer, or with pruritus, a burning sensation, pain, or bleeding.

Disease Ontology 11 Vulva cancer: A female reproductive organ cancer that is located in the vulva.

Vulva carcinoma: A vulva cancer that has material basis in abnormally proliferating cells derives from epithelial cells.

Wikipedia: 75 Vulvar cancer is a cancer of the vulva, the outer portion of the female genitals. It most commonly... more...
Sources

Related Diseases for Vulva Cancer

About this section

Diseases related to Vulva Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 621)
# Related Disease Score Top Affiliating Genes
1 vulvar sebaceous carcinoma 32.1 TP53 KRT7
2 vulvar eccrine porocarcinoma 32.1 PIP CDKN2A
3 vulva basal cell carcinoma 32.0 ERBB2 CDKN2A
4 vulvar melanoma 32.0 MIR19B1 HRAS CD274
5 vulva adenocarcinoma 32.0 PIP KRT7 ERBB2
6 bartholin's gland carcinoma 31.8 MIR590 MIR4712 MIR3147 MIR19B1 KRT7
7 cervical adenocarcinoma 30.5 TP53 KRT7 CDKN2A
8 human papillomavirus infectious disease 30.5 TP53 PTEN PIK3CA MIR223 MIR19B1 MIR100
9 verrucous carcinoma 30.4 TP53 PIK3CA GP5 EGFR CDKN2A
10 lymphangitis 30.4 KRT7 ERBB2 EGFR
11 keratinizing squamous cell carcinoma 30.2 TP53 PIK3CA KRT7 HRAS EGFR CDKN2A
12 basaloid squamous cell carcinoma 30.2 TP53 KRT7 CDKN2A
13 papilloma 30.2 TP53 PTEN KRT7 ERBB2 EGFR CDKN2A
14 anogenital venereal wart 30.2 TP53 GP5 CDKN2A
15 adenosquamous carcinoma 30.2 KRT7 HRAS EGFR
16 clear cell hidradenoma 30.1 PIP KRT7
17 small cell carcinoma 30.1 TP53 PTEN KRT7 EGFR
18 paget disease, extramammary 30.0 PIP KRT7 ERBB2
19 mammary paget's disease 30.0 PIP KRT7 ERBB2
20 keratoacanthoma 30.0 TP53 PIK3CA EGFR
21 mucosal melanoma 30.0 PTEN HRAS CDKN2A CD274
22 lipomatosis, multiple 30.0 TP53 PTEN PIK3CA
23 vulval paget's disease 30.0 PIP KRT7 ERBB2 CDKN2A
24 ovarian carcinosarcoma 30.0 TP53 PIK3CA HRAS ERBB2
25 sweat gland cancer 30.0 TP53 PIP KRT7 ERBB2
26 skin benign neoplasm 29.9 TP53 PIP KRT7 HRAS
27 endometrial hyperplasia 29.9 TP53 PTEN CDKN2A
28 keratosis 29.9 TP53 PIK3CA HRAS EGFR CDKN2A
29 lymphangioma 29.9 TP53 PIK3CA KRT7 HRAS EGFR
30 large cell carcinoma 29.9 TP53 KRT7 HRAS ERBB2 EGFR
31 cervical squamous cell carcinoma 29.8 TP53 PTEN PIK3CA EGFR CDKN2A
32 suppressor of tumorigenicity 3 29.8 TP53 CDKN2A
33 muir-torre syndrome 29.8 TP53 PTEN KRT7 HRAS CDKN2A
34 cervical cancer 29.7 TP53 PTEN PIK3CA HRAS ERBB2 CDKN2A
35 transitional cell carcinoma 29.7 TP53 PTEN KRT7 ERBB2 EGFR
36 intrahepatic cholangiocarcinoma 29.7 TP53 KRT7 HRAS ERBB2 EGFR CD274
37 apocrine adenocarcinoma 29.7 TP53 PIP PIK3CA KRT7 ERBB2 EGFR
38 anus cancer 29.7 TP53 PIK3CA KRT7 HRAS GP5 ERBB2
39 penile cancer 29.7 TP53 PIK3CA MIR223 GP5 EGFR CDKN2A
40 adenoid cystic carcinoma 29.6 TP53 PTEN PIK3CA KRT7 HRAS ERBB2
41 squamous cell carcinoma 29.6 TP53 PTEN PIK3CA KRT7 HRAS ERBB2
42 skin melanoma 29.6 TP53 PTEN PIK3CA HRAS ERBB2 CDKN2A
43 basal cell carcinoma 29.6 TP53 PTEN PIP MIR19B1 KRT7 EGFR
44 vaginal cancer 29.4 TP53 PTEN KRT7 HRAS GP5 EGFR
45 squamous cell carcinoma, head and neck 29.4 TP53 PTEN PIK3CA HRAS ERBB2 EGFR
46 endometrial cancer 29.3 TP53 PTEN PIK3CA KRT7 HRAS ERBB2
47 cholangiocarcinoma 29.3 TP53 PTEN PIK3CA KRT7 ERBB2 EGFR
48 skin carcinoma 29.3 TP53 PTEN KRT7 HRAS ERBB2 EGFR
49 carcinosarcoma 29.3 TP53 PTEN PIK3CA KRT7 HRAS ERBB2
50 skin disease 29.2 TP53 PTEN PIK3CA MIR223 MIR19B1 HRAS

Comorbidity relations with Vulva Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Clitoris Cancer
Hypertension, Essential Localized Scleroderma
Vaginal Cancer Vulvar Dystrophy

Graphical network of the top 20 diseases related to Vulva Cancer:



Diseases related to Vulva Cancer
Sources

Symptoms & Phenotypes for Vulva Cancer

About this section

UMLS symptoms related to Vulva Cancer:


pelvic pain; pruritus vulvae

GenomeRNAi Phenotypes related to Vulva Cancer according to GeneCards Suite gene sharing:

25 (show all 17)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.43 EGFR HRAS PIK3CA
2 Decreased viability GR00055-A-2 10.43 EGFR HRAS PIK3CA
3 Decreased viability GR00107-A-1 10.43 WEE1
4 Decreased viability GR00221-A-1 10.43 CDKN2A EGFR HRAS PIK3CA WEE1
5 Decreased viability GR00221-A-2 10.43 HRAS PIK3CA WEE1
6 Decreased viability GR00221-A-3 10.43 CDKN2A HRAS ERBB2
7 Decreased viability GR00221-A-4 10.43 CDKN2A EGFR PIK3CA WEE1 ERBB2
8 Decreased viability GR00231-A 10.43 WEE1
9 Decreased viability GR00240-S-1 10.43 WEE1
10 Decreased viability GR00249-S 10.43 WEE1
11 Decreased viability GR00301-A 10.43 WEE1
12 Decreased viability GR00342-S-1 10.43 WEE1
13 Decreased viability GR00342-S-2 10.43 WEE1
14 Decreased viability GR00342-S-3 10.43 WEE1
15 Decreased viability GR00386-A-1 10.43 WEE1
16 Decreased viability GR00402-S-2 10.43 PIK3CA WEE1
17 Increased cell death in HCT116 cells GR00103-A-0 8.62 PIK3CA WEE1

MGI Mouse Phenotypes related to Vulva Cancer:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.7 CDKN2A EGFR ERBB2 HRAS PIK3CA PTEN
2 digestive/alimentary MP:0005381 9.56 CDKN2A EGFR ERBB2 HRAS PIK3CA PIP
3 cellular MP:0005384 9.44 CD274 CDKN2A EGFR ERBB2 KRT7 MIR100
Sources

Drugs & Therapeutics for Vulva Cancer

About this section

Drugs for Vulva Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 100)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
2
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
3 Vaccines Phase 3
4 Hemostatics Phase 3
5 Antineoplastic Agents, Hormonal Phase 3
6 Gastrointestinal Agents Phase 3
7 Fibrin Tissue Adhesive Phase 3
8 Coagulants Phase 3
9
Bupropion Approved Phase 2 31677-93-7, 34841-39-9, 34911-55-2 444
10
Dopamine Approved Phase 2 62-31-7, 51-61-6 681
11
Fondaparinux Approved, Investigational Phase 2 114870-03-0, 104993-28-4 5282448 636380
12
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
13
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
14
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
15
Bleomycin Approved, Investigational Phase 2 9041-93-4, 11056-06-7 5360373
16
Atezolizumab Approved, Investigational Phase 1, Phase 2 1380723-44-3
17
Levoleucovorin Approved, Experimental, Investigational Phase 1, Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
18
Niraparib Approved, Investigational Phase 1, Phase 2 1038915-60-4 24958200
19
Irinotecan Approved, Investigational Phase 1, Phase 2 97682-44-5, 100286-90-6 60838
20
Fluorouracil Approved Phase 1, Phase 2 51-21-8 3385
21
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
22
Gemcitabine Approved Phase 2 95058-81-4, 122111-03-9 60750
23
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
24
Fludarabine Approved Phase 1, Phase 2 75607-67-9, 21679-14-1 30751 657237
25
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
26
Aldesleukin Approved Phase 1, Phase 2 110942-02-4
27
Folic acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-30-3 6037
28
Entinostat Investigational Phase 1, Phase 2 209783-80-2 4261
29 Dopamine Uptake Inhibitors Phase 2
30 Dopamine Agents Phase 2
31 Psychotropic Drugs Phase 2
32 Antidepressive Agents Phase 2
33 Cytochrome P-450 Enzyme Inhibitors Phase 2
34 HIV Protease Inhibitors Phase 2
35
protease inhibitors Phase 2
36 Fibrinolytic Agents Phase 2
37 Factor Xa Inhibitors Phase 2
38 PENTA Phase 2
39 Anticoagulants Phase 2
40 Serine Proteinase Inhibitors Phase 2
41 Antithrombins Phase 2
42 Antithrombin III Phase 2
43 Immunologic Factors Phase 1, Phase 2
44 Albumin-Bound Paclitaxel Phase 2
45 Antimitotic Agents Phase 2
46 Tubulin Modulators Phase 2
47 Alkylating Agents Phase 1, Phase 2
48 Antirheumatic Agents Phase 1, Phase 2
49 Antineoplastic Agents, Alkylating Phase 1, Phase 2
50 Anti-Infective Agents Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 146)
# Name Status NCT ID Phase Drugs
1 A Study to Evaluate the Efficacy of Quadrivalent HPV Vaccine in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related CIN, AIS, and Cervical Cancer, and HPV 6-, 11-, 16-, and 18-Related External Genital Warts, Vulvar Intraepithelial Neoplasia Vaginal Intraepithelial Neoplasia, Vulvar Cancer, and Vaginal Cancer in 16- to 23-Year-Old Women Completed NCT00092521 Phase 3
2 A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 16- to 26- Year-Old Women Completed NCT00543543 Phase 3
3 Phase III Double-Blind Study Of Depot Octreotide Versus Placebo In The Prevention Of Acute Diarrhea In Patients Receiving Pelvic Radiation Therapy Completed NCT00033605 Phase 3 octreotide acetate
4 A Phase III Clinical Trial Use of TISSEEL VH Fibrin Sealant to Reduce Lymphedema Incidence After Inguinal Lymph Node Dissection Performed in the Management of Vulvar Malignancies Completed NCT00028951 Phase 3 fibrin sealant
5 Phase III Radiation Therapy vs Pelvic Node Resection for Previously Untreated Invasive Squamous Cell Carcinoma of the Vulva With Positive Groin Nodes Completed NCT00898352 Phase 3
6 A Phase III Clinical Trial to Study the Immunogenicity, Tolerability, and Manufacturing Consistency of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (9 to 15 Year Olds) With a Comparison to Young Women (16 to 26 Year Olds) Completed NCT00943722 Phase 3
7 An Open-Label Phase III Clinical Trial to Study the Immunogenicity and Tolerability of GARDASIL®9 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Adult Women (27- to 45-Year-Olds) Compared to Young Adult Women (16 to 26 Year Olds) Completed NCT03158220 Phase 3
8 A Randomized, Double-Blind and Positive-Controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of the 4-valent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Hansenula Polymorpha) and 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years Completed NCT04425291 Phase 3
9 Intraoperative Lymphatic Mapping in Patients With Stage I and II Squamous Carcinoma of the Vulva Completed NCT00003325 Phase 3
10 A Randomized, Double-Blind and Positive-Controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged16-26 Years Completed NCT05372016 Phase 3
11 A Phase III Open-label Safety and Immunogenicity Study of GARDASILâ„¢9 Administered to 9- to 26-Year-Old Females and Males in Vietnam Completed NCT03546842 Phase 3
12 Prospective and Randomized Study to Evaluate Interest of Ultracision Use in Inguinal Lymph Nodes Curage. Completed NCT00224744 Phase 3
13 A Phase III, Randomized, International, Placebo-Controlled, Double-Blind Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given to Females 12-26 Years of Age Who Have Previously Received GARDASILâ„¢ Completed NCT01047345 Phase 3
14 Evaluating the Immunogenicity and Safety of 9-valent Human Papillomavirus(Type6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine in Chinese Females Aged 9 to 45 Years: A Phase 3, Open-label, Non-randomised Clinical Trial Recruiting NCT04895020 Phase 3
15 A Multicenter,Randomized,Blind and Positive-Controlled Phase â…¢ Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years Recruiting NCT04422366 Phase 3
16 Reliability of Indocyanine Green Use in Sentinel Lymph Node Identification in Cancer Surgery Recruiting NCT02997553 Phase 3 Indocyanine green;Technetium99
17 A Prospective Randomized Single Blind Phase III Trial Comparing Flexitouch Home Maintenance Therapy to Standard Home Maintenance Therapy for Lower Extremity Lymphedema Resulting From Treatment of Gynecologic Malignancy Terminated NCT00577317 Phase 3
18 A Randomized Study of Adjuvant Radiation Treatment Versus Radiation and Chemotherapy in Patients With Vulvar Cancer and Involved Nodes Terminated NCT00006096 Phase 3 cisplatin
19 Systematic Nutritional Care in Patients Receiving First-line Chemotherapy for Metastatic Gynecologic Cancer in a Phase II Study Unknown status NCT00905658 Phase 2
20 Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women With Breast or Gynecologic Cancer Completed NCT03180294 Phase 2 Bupropion 150 mg XL;Placebo
21 A Limited Access Phase II Trial Utilizing Bioimpedance to Measure Lower Extremity Lymphedema Associated With the Surgical Management of a Vulvar Cancer Completed NCT01406769 Phase 2
22 A Prospective Evaluation of a Palliative Radio-Surgical Approach for the Treatment of Gynecologic Malignancies Completed NCT01079832 Phase 2
23 Psychosexual Intervention for Gynecologic and Breast Cancer Patients Completed NCT01764802 Phase 2
24 A Phase II Trial of Radiation Therapy and Weekly Cisplatin Chemotherapy for the Treatment of Locally-Advanced Squamous Cell Carcinoma of the Vulva Completed NCT00068406 Phase 2 Cisplatin
25 A Randomized, Double-Blinded, Tolerability and Immunogenicity Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered Concomitantly With GARDASIL to 16- to 26- Year-Old Women Completed NCT00551187 Phase 2
26 A Phase IIa Randomized, Double-Blind Controlled With Gardasil, Clinical Trial to Study theTolerability and Immunogenicity of V505 (a Multivalent Human Papilloma Virus [HPV] L1 Virus Like Particle [VLP] Vaccine) in Healthy 16 to 26 Year Old Women Completed NCT00520598 Phase 2 Comparator: V505 formulation 2
27 The Impact of the Self-management Intervention "WOMAN-PRO II Program" on Patients With Vulvar Neoplasia to Minimize Post-surgical Symptom Prevalence: A Mixed-Methods Project Completed NCT01986725 Phase 2
28 Women's Cancer Center Protocol #45: Prolonged Venous Thromboembolism Prophylaxis With Fondaparinux in Gynecologic Oncology Patients: An Open Label Phase II Trial Completed NCT00381888 Phase 2 fondaparinux sodium
29 Effectiveness of an Individualized Symptom Education Program (ISEP) on the Symptom Distress of Women Receiving Radiation for Gynecological Cancer. Completed NCT00275353 Phase 2
30 Phase II Clinical Trial On Taxol As Single Agent In Locally Advanced And/Or Metastatic Or Recurrent Vulva Cancer Not Amenable For Surgery And/Or Radiotherapy Completed NCT00014599 Phase 2 paclitaxel
31 A Pilot Study Evaluating The Safety Of Avastin And Pelvic Radiation In Women With Pelvic-Confined Recurrence of Gynecological Cancers Completed NCT00545792 Phase 2 Avastin
32 A Clinical Trial to Evaluate Image-Guided Gynecologic Brachytherapy in the Advanced Multimodality Image-Guided Operating Suite (AMIGO) Completed NCT01399658 Phase 2 3'-Deoxy-3'-18f-Fluorothymidine
33 Treatment of Locally Advanced VULvar CArcinoma in a Neoadjuvant Setting With Carboplatin and Paclitaxel Chemotherapy (VULCANize) Recruiting NCT04192253 Phase 2 Paclitaxel and Carboplatin
34 Treatment of Metastatic Vulvar Carcinoma With Carboplatin and Paclitaxel Chemotherapy (CRAVAT) Recruiting NCT04161664 Phase 2 Paclitaxel and Carboplatin
35 A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158) Recruiting NCT02628067 Phase 2
36 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
37 A Randomized Phase II Trial of Adjuvant Nivolumab With or Without Cabozantinib in Patients With Resected Mucosal Melanoma Recruiting NCT05111574 Phase 2 Cabozantinib S-malate;Placebo Administration
38 Electrochemotherapy With Carboplatinum Plus Bleomycin Versus Bleomycin Alone in Vulvar Cancer: the ElechtraPlatinum Study. A Randomized Controlled Trial Recruiting NCT05395962 Phase 2 Carboplatin;Bleomycin
39 Groningen International Study on Sentinel Nodes in Vulvar Cancer-III, a Prospective Phase II Treatment Trial Recruiting NCT05076942 Phase 2 Cisplatin
40 A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers Recruiting NCT04708470 Phase 1, Phase 2 Bintrafusp Alfa;NHS-IL12;Entinostat
41 A Multilevel Intervention (Potlako+) to Improve Timely Cancer Detection and Treatment Recruiting NCT04141449 Phase 2
42 Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers ( Adaptive PET II) Recruiting NCT03403465 Phase 2
43 A Phase 2 Study of Combined Chemo-immunotherapy With Cisplatin-pembrolizumab and Radiation for Unresectable Vulvar Squamous Cell Carcinoma Recruiting NCT04430699 Phase 2 Cisplatin;Pembrolizumab
44 Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types Recruiting NCT05000294 Phase 1, Phase 2 Atezolizumab;Tivozanib
45 A Phase I/II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 for HPV-Associated Cancers Recruiting NCT02858310 Phase 1, Phase 2 Aldesleukin;Fludarabine;Cyclophosphamide
46 A Phase 1/2a, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of PEN-866 in Patients With Advanced Solid Malignancies Recruiting NCT03221400 Phase 1, Phase 2 PEN-866 Sodium;fluorouracil;Folinic acid;Niraparib
47 A Phase 2, Open-Label Study to Evaluate Efficacy of Combination Treatment With MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients With Recurrent/Metastatic Human Papilloma Virus Associated Cancers Active, not recruiting NCT03439085 Phase 2
48 A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent With Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva (NCT #01595061) Active, not recruiting NCT01595061 Phase 2 Cisplatin;Gemcitabine Hydrochloride
49 Phase II Basket Trial Evaluating the Efficacy of a Combination of Pembrolizumab and Vorinostat in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma Active, not recruiting NCT04357873 Phase 2 pembrolizumab; vorinostat
50 A Feasibility Study of E7 TCR-T Cell Induction Therapy for Locoregionally Advanced HPV-Associated Cancers Not yet recruiting NCT05639972 Phase 1, Phase 2 Conditioning, E7 TCR-T cells, and aldesleukin

Search NIH Clinical Center for Vulva Cancer

Cochrane evidence based reviews: vulvar neoplasms

Sources

Genetic Tests for Vulva Cancer

About this section
Sources

Anatomical Context for Vulva Cancer

About this section

Organs/tissues related to Vulva Cancer:

FMA: Vulva
MalaCards : Lymph Node, Skin, Cervix, T Cells, Breast, Colon, Liver
Sources

Publications for Vulva Cancer

About this section

Articles related to Vulva Cancer:

(show top 50) (show all 2866)
# Title Authors PMID Year
1
Perforator flaps for vulvar reconstruction: basic principles. 62 41
36300233 2022
2
Performance of Indocyanine Green Compared to 99mTc-Nanocolloids for Sentinel Lymph Node Detection in Early Vulvar Cancer. 62 41
36354698 2022
3
The First Human Vulvar Intraepithelial Neoplasia Cell Line with Naturally Infected Episomal HPV18 Genome. 41
36146860 2022
4
Comparison of delphinidin, quercetin and (-)-epigallocatechin-3-gallate as inhibitors of the EGFR and the ErbB2 receptor phosphorylation. 53 62
18618485 2008
5
The anthocyanidins cyanidin and delphinidin are potent inhibitors of the epidermal growth-factor receptor. 53 62
11262056 2001
6
Signaling by epidermal growth factor differentially affects integrin-mediated adhesion of tumor cells to extracellular matrix proteins. 53 62
8912181 1996
7
Incidence and predictors of toxicity in the management of vulvar squamous cell carcinoma treated with radiation therapy. 62
36281250 2022
8
Guideline-Discordant Care in Early-Stage Vulvar Cancer. 62
36357957 2022
9
Breast, Ovarian, Uterine, Vaginal, and Vulvar Cancer Care in Low- and Middle-Income Countries: Prevalence, Screening, Treatment, Palliative Care, and Human Resources Training. 62
36328680 2022
10
'Case of the Month' from University Medical Center Hamburg-Eppendorf, Germany: vulvar cancer after female-male gender reassignment. 62
36468240 2022
11
Detection rates of sentinel lymph node in vulvar cancer using the new protocol with indocyanine-green fluorescence: Time to abandon both blue dye as well as 99mTc-labeled colloid lymphoscintigraphy protocols? 62
36379861 2022
12
Observational multicenter Italian study on vulvar cancer adjuvant radiotherapy (OLDLADY 1.2): a cooperation among AIRO Gyn, MITO and MaNGO groups. 62
36088437 2022
13
Inguinofemoral sentinel lymph node biopsy by scar injection in vulvar cancer: an assessment of feasibility and long-term outcomes. 62
36332935 2022
14
Robot-assisted single-port surgery in inguinal lymph-node dissection for vulvar cancer. 62
35718609 2022
15
Trends in HPV- and non-HPV-associated vulvar cancer incidence, United States, 2001-2017. 62
36240909 2022
16
Postpartum regression of human papillomavirus-related vulvar cancer: A case report. 62
35975323 2022
17
Coverage probability planning for simultaneously integrated boosts of inguinal lymph nodes in vulvar cancer. 62
36369704 2022
18
Can late lymphoscintigraphy be omitted in the sentinel node procedure in early-stage vulvar cancer? 62
36412099 2022
19
Characterization of patients with vulvar lichen sclerosus and association to vulvar carcinoma: a retrospective single center analysis. 62
36409332 2022
20
Locally advanced vulvar carcinoma diagnosed during cervical cancer screening. 62
36343970 2022
21
Prostaglandin E2 receptor EP1 expression in vulvar cancer. 62
36436093 2022
22
Vulvar Cancer Incidence in the United States and its Relationship to Human Papillomavirus Vaccinations, 2001-2018. 62
35969832 2022
23
The Unmet Needs in the Management of Vulvar Cancer and a Review of Indian Literature. 62
36417690 2022
24
The changing role for extended resections in an era of advanced radiotherapy techniques and novel therapies in gynaecological malignancy. 62
36184421 2022
25
Data Set for the Reporting of Carcinomas of the Vulva: Recommendations From the International Collaboration on Cancer Reporting (ICCR). 62
36305532 2022
26
Tubulovillous adenoma with high-grade dysplasia of the vulva harboring high tumor mutational burden and cancer-associated mutations: a case report. 62
36307835 2022
27
Unusual echocardiographic finding as cause of acute coronary syndrome with ST- segment elevation. 62
36191246 2022
28
"Intestinal-Type" Vulvar Adenocarcinoma: A Review of the MITO Rare Tumors Group. 62
36291953 2022
29
Verrucous carcinoma of the vulva: Patterns of care and treatment outcomes. 62
35075817 2022
30
Neoadjuvant chemotherapy followed by radical surgery in locally advanced vulvar carcinoma: a single-institution experience. 62
34289750 2022
31
An Unusual Case of Vulvar Involvement in the Course of Granulomatosis with Polyangiitis. 62
36360741 2022
32
When is it safe to omit contralateral groin management in unilateral sentinel node-positive early stage vulvar cancer? 62
36180166 2022
33
Fertility-sparing treatment of locally advanced vulvar squamous cell carcinoma in a young patient. 62
36158735 2022
34
Time to completion of radiation treatment in locally advanced squamous cell carcinoma of the vulva and the impact on survival. 62
36154760 2022
35
Perineural Invasion as a Predictive Biomarker of Groin Metastases and Survival Outcomes in Vulvar Cancer: A Meta-Analysis. 62
35467488 2022
36
Changes in HPV prevalence in Danish women with vulvar cancer during 28 years - A nationwide study of >1300 cancer cases. 62
35750502 2022
37
The role of adjuvant radiation therapy in older patients with node-positive vulvar cancer: A national cancer database analysis. 62
36150913 2022
38
Response to letter to editor: indocyanine green fluorescent image-guided inguinal sentinel node biopsy for vulvar cancer: criteria and intraoperative challenges. 62
35681268 2022
39
Neoadjuvant chemotherapy for patients with locally advanced vulvar cancer. 62
35943437 2022
40
Indocyanine green fluorescent image-guided inguinal sentinel node biopsy for vulvar cancer: criteria and intraoperative challenges. 62
35681269 2022
41
A comparison of ICG-NIR with blue dye and technetium for the detection of sentinel lymph nodes in vulvar cancer. 62
36207232 2022
42
Superficial versus deep inguinal nodal dissection for vulvar cancer staging. 62
35781163 2022
43
Vulvar tumor in an infant. 62
36206215 2022
44
Medicaid expansion and 2-year survival in women with gynecologic cancer: a difference-in-difference analysis. 62
35500609 2022
45
T-Cell Density at the Invasive Margin and Immune Phenotypes Predict Outcome in Vulvar Squamous Cell Cancer. 62
36077784 2022
46
Vulval Intraepithelial Neoplasia 3: A Clinico-Pathological Review in a Tertiary Care Centre Over 10 Years. 62
35928075 2022
47
HPV-negative Penile Intraepithelial Neoplasia (PeIN) With Basaloid Features. 62
35297786 2022
48
Single centre experience of 800 gynaecologic oncology cases in 2020: influence of pandemy on cancer surgeries. 62
35476608 2022
49
Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study. 62
35361487 2022
50
An update on current pharmacotherapy for vulvar cancer. 62
36002936 2022
Sources

Variations for Vulva Cancer

About this section

Cosmic variations for Vulva Cancer:

8 (show top 50) (show all 3457)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM105721382 HRAS skin,genital,carcinoma,squamous cell carcinoma c.182A>T p.Q61L 11:533874-533874 6
2 COSM112988842 HRAS skin,genital,carcinoma,squamous cell carcinoma c.182A>T p.Q61L 11:533874-533874 6
3 COSM84510986 ZNF276 skin,NS,carcinoma,basal cell carcinoma c.*940C>T p.? 16:89739186-89739186 5
4 COSM149268805 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.1261G>A p.G421R 16:72958885-72958885 5
5 COSM87274302 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.1655C>T p.S552F 16:72958491-72958491 5
6 COSM87270496 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.10847C>T p.S3616F 16:72787429-72787429 5
7 COSM149259613 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.10847C>T p.S3616F 16:72787429-72787429 5
8 COSM149268792 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.5825G>A p.G1942E 16:72796857-72796857 5
9 COSM87274307 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.1261G>A p.G421R 16:72958885-72958885 5
10 COSM149268800 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.1655C>T p.S552F 16:72958491-72958491 5
11 COSM87273325 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.2084C>T p.P695L 16:72958062-72958062 5
12 COSM149304906 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.1991C>T p.S664F 16:72958155-72958155 5
13 COSM87296537 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.11050G>A p.D3684N 16:72787226-72787226 5
14 COSM102023150 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.-23-7526C>T p.? 16:72958491-72958491 5
15 COSM102023155 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.-23-7920G>A p.? 16:72958885-72958885 5
16 COSM102019420 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.8105C>T p.S2702F 16:72787429-72787429 5
17 COSM149331772 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.11050G>A p.D3684N 16:72787226-72787226 5
18 COSM102023144 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.3083G>A p.G1028E 16:72796857-72796857 5
19 COSM102047764 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.8308G>A p.D2770N 16:72787226-72787226 5
20 COSM87286441 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.1991C>T p.S664F 16:72958155-72958155 5
21 COSM102036925 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.-23-7190C>T p.? 16:72958155-72958155 5
22 COSM149266372 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.2084C>T p.P695L 16:72958062-72958062 5
23 COSM102022243 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.-23-7097C>T p.? 16:72958062-72958062 5
24 COSM87274293 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.5825G>A p.G1942E 16:72796857-72796857 5
25 COSM104882801 XPO1 skin,NS,carcinoma,basal cell carcinoma c.782G>A p.R261Q 2:61496985-61496985 5
26 COSM104236272 XPO1 skin,NS,carcinoma,basal cell carcinoma c.782G>A p.R261Q 2:61496985-61496985 5
27 COSM101976974 XPO1 skin,NS,carcinoma,basal cell carcinoma c.782G>A p.R261Q 2:61496985-61496985 5
28 COSM87040659 TSC2 skin,NS,carcinoma,basal cell carcinoma c.869C>T p.P290L 16:2058767-2058767 5
29 COSM101179498 TSC2 skin,NS,carcinoma,basal cell carcinoma c.1913C>T p.S638F 16:2071897-2071897 5
30 COSM150324396 TSC2 skin,NS,carcinoma,basal cell carcinoma c.869C>T p.P290L 16:2058767-2058767 5
31 COSM101191558 TSC2 skin,NS,carcinoma,basal cell carcinoma c.722C>T p.P241L 16:2058767-2058767 5
32 COSM147706701 TSC2 skin,NS,carcinoma,basal cell carcinoma c.869C>T p.P290L 16:2058767-2058767 5
33 COSM150353664 TSC2 skin,NS,carcinoma,basal cell carcinoma c.2060C>T p.S687F 16:2071897-2071897 5
34 COSM151748023 TSC2 skin,NS,carcinoma,basal cell carcinoma c.679T>A p.C227S 16:2056674-2056674 5
35 COSM150576157 TSC2 skin,NS,carcinoma,basal cell carcinoma c.679T>A p.C227S 16:2056674-2056674 5
36 COSM149802478 TSC2 skin,NS,carcinoma,basal cell carcinoma c.679T>A p.C227S 16:2056674-2056674 5
37 COSM148980439 TSC2 skin,NS,carcinoma,basal cell carcinoma c.2060C>T p.S687F 16:2071897-2071897 5
38 COSM90415129 TSC2 skin,NS,carcinoma,basal cell carcinoma c.869C>T p.P290L 16:2058767-2058767 5
39 COSM149800636 TSC2 skin,NS,carcinoma,basal cell carcinoma c.2060C>T p.S687F 16:2071897-2071897 5
40 COSM148991757 TSC2 skin,NS,carcinoma,basal cell carcinoma c.869C>T p.P290L 16:2058767-2058767 5
41 COSM151753165 TSC2 skin,NS,carcinoma,basal cell carcinoma c.869C>T p.P290L 16:2058767-2058767 5
42 COSM151513825 TSC2 skin,NS,carcinoma,basal cell carcinoma c.679T>A p.C227S 16:2056674-2056674 5
43 COSM151371066 TSC2 skin,NS,carcinoma,basal cell carcinoma c.679T>A p.C227S 16:2056674-2056674 5
44 COSM148982237 TSC2 skin,NS,carcinoma,basal cell carcinoma c.679T>A p.C227S 16:2056674-2056674 5
45 COSM136628294 TSC2 skin,NS,carcinoma,basal cell carcinoma c.902C>T p.P301L 16:2058767-2058767 5
46 COSM110103971 TSC2 skin,NS,carcinoma,basal cell carcinoma c.568T>A p.C190S 16:2056674-2056674 5
47 COSM150583851 TSC2 skin,NS,carcinoma,basal cell carcinoma c.869C>T p.P290L 16:2058767-2058767 5
48 COSM102616914 TSC2 skin,NS,carcinoma,basal cell carcinoma c.2060C>T p.S687F 16:2071897-2071897 5
49 COSM136618116 TSC2 skin,NS,carcinoma,basal cell carcinoma c.712T>A p.C238S 16:2056674-2056674 5
50 COSM110102044 TSC2 skin,NS,carcinoma,basal cell carcinoma c.1949C>T p.S650F 16:2071897-2071897 5
Sources

Expression for Vulva Cancer

About this section
Search GEO for disease gene expression data for Vulva Cancer.
Sources

Pathways for Vulva Cancer

About this section

Pathways related to Vulva Cancer according to GeneCards Suite gene sharing:

(show all 43)
# Super pathways Score Top Affiliating Genes
1
TNFR1 Pathway 64
Show member pathways
 12.89 TP53 PTEN PIK3CA HRAS EGFR CDKN2A
2
NFAT and Cardiac Hypertrophy 64
Show member pathways
 12.82 PTEN PIK3CA HRAS ERBB2 EGFR
3
Signaling by Receptor Tyrosine Kinases 66
12.8 PIK3CA HRAS ERBB2 EGFR CD274
4
Immune response IL-23 signaling pathway 22
Show member pathways
 12.56 TP53 PIK3CA HRAS ERBB2 EGFR
5
Endometrial cancer 74
Show member pathways
 12.53 TP53 PTEN PIK3CA HRAS ERBB2 EGFR
6
Development EGFR signaling pathway 22
Show member pathways
 12.43 TP53 PIK3CA HRAS ERBB2 EGFR
7
Hepatocyte growth factor receptor signaling 74
Show member pathways
 12.41 ERBB2 HRAS PIK3CA PTEN TP53
8
Malignant pleural mesothelioma 74
12.41 CD274 CDKN2A EGFR HRAS PIK3CA PTEN
9
NF-kappaB Pathway 70
Show member pathways
 12.37 TP53 PIK3CA HRAS ERBB2 EGFR
10
Breast cancer pathway 74
Show member pathways
 12.37 EGFR ERBB2 HRAS PIK3CA PTEN TP53
11
Development Ligand-independent activation of ESR1 and ESR2 22
Show member pathways
 12.29 PIK3CA HRAS ERBB2 EGFR
12
Focal adhesion 74
12.23 PTEN PIK3CA HRAS ERBB2 EGFR
13
Development IGF-1 receptor signaling 22
Show member pathways
 12.22 HRAS PIK3CA PTEN TP53
14
Signaling by ERBB2 KD Mutants 66
Show member pathways
 12.2 PIK3CA HRAS ERBB2 EGFR
15
MAPK Signaling: Mitogens 65
Show member pathways
 12.14 TP53 PTEN PIK3CA HRAS ERBB2 EGFR
16
Integrated breast cancer pathway 74
12.12 WEE1 TP53 PTEN EGFR
17
T-cell activation SARS-CoV-2 74
Show member pathways
 12.09 TP53 PTEN PIK3CA HRAS CDKN2A
18
mTOR Signaling 65
12.07 TP53 PTEN ERBB2 EGFR
19
Transcription Androgen Receptor nuclear signaling 22
Show member pathways
 12.06 PTEN PIK3CA HRAS ERBB2 EGFR
20
Signaling by ERBB4 66
Show member pathways
 12.05 PIK3CA HRAS ERBB2 EGFR
21
Signaling by ERBB2 66
Show member pathways
 12.02 EGFR ERBB2 HRAS PIK3CA
22
MAPK Pathway 70
Show member pathways
 12 TP53 PIK3CA ERBB2 EGFR
23
Gastrin signaling pathway 74
11.94 PIK3CA HRAS EGFR CDKN2A
24
Senescence and autophagy in cancer 74
11.89 TP53 PTEN HRAS CDKN2A
25
Signaling by EGFR 66
Show member pathways
 11.86 PIK3CA HRAS EGFR
26
Small cell lung cancer 74
11.85 TP53 PTEN PIK3CA
27
Development EGFR signaling via small GTPases 22
Show member pathways
 11.85 PTEN PIK3CA HRAS ERBB2 EGFR
28
Thyroid hormones production and peripheral downstream signaling effects 74
11.78 TP53 PIK3CA HRAS
29
mTOR Pathway 70
Show member pathways
 11.75 TP53 PIK3CA HRAS
30
DNA damage response (only ATM dependent) 74
11.73 TP53 PTEN PIK3CA HRAS ERBB2
31
AP-1 transcription factor network 61
11.68 CDKN2A PTEN TP53
32
BCR signaling pathway 61
11.65 PTEN PIK3CA HRAS
33
miRNAs involved in DNA damage response 74
11.65 MIR100 MIR19B1 MIR223 TP53
34
Copper homeostasis 74
Show member pathways
 11.6 TP53 PTEN PIK3CA
35
IL-2 Gene Expression in Activated and Quiescent T-Cells 64
Show member pathways
 11.6 PIK3CA HRAS ERBB2 EGFR
36
Agrin Interactions at Neuromuscular Junction 64
11.58 HRAS ERBB2 EGFR
37
Pathways affected in adenoid cystic carcinoma 74
11.35 TP53 PTEN PIK3CA HRAS ERBB2
38
a6b1 and a6b4 Integrin signaling 61
11.3 PIK3CA HRAS ERBB2 EGFR
39
PI3K-AKT-mTOR signaling pathway and therapeutic opportunities 74
11.25 PTEN PIK3CA HRAS
40
Extracellular vesicle-mediated signaling in recipient cells 74
11.21 HRAS ERBB2 EGFR
41
Head and neck squamous cell carcinoma 74
11.03 TP53 PTEN PIK3CA HRAS ERBB2 EGFR
42
Bladder cancer 74
10.96 TP53 HRAS ERBB2 EGFR CDKN2A
43
Relationship between inflammation, COX-2 and EGFR 74
10.68 PIK3CA EGFR
Sources

GO Terms for Vulva Cancer

About this section

Biological processes related to Vulva Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.92 TP53 PIP MIR223 HRAS ERBB2 CDKN2A
2 negative regulation of gene expression GO:0010629 9.7 TP53 PIK3CA MIR19B1 MIR100 HRAS
3 phosphatidylinositol 3-kinase signaling GO:0014065 9.43 PTEN PIK3CA ERBB2
4 positive regulation of miRNA maturation GO:1903800 9.26 TP53 EGFR
5 negative regulation of immature T cell proliferation in thymus GO:0033088 8.8 ERBB2 CDKN2A

Molecular functions related to Vulva Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA base-pairing translational repressor activity GO:1903231 9.02 MIR590 MIR425 MIR223 MIR19B1 MIR100
Sources

Sources for Vulva Cancer

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....